Chemomab Therapeutics has been granted a patent for a pharmaceutical composition that includes isolated anti-CCL24 (eotaxin 2) antibodies. This composition is designed for treating intrahepatic cholestatic liver diseases, featuring a fully humanized antibody with specific sequence homologies. GlobalData’s report on Chemomab Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Chemomab Therapeutics, Human telomerase RT biomarker was a key innovation area identified from patents. Chemomab Therapeutics's grant share as of July 2024 was 45%. Grant share is based on the ratio of number of grants to total number of patents.
Anti ccl24 antibodies for treating hepatic pathologies
The granted patent US12018074B2 presents a pharmaceutical composition specifically designed for the treatment of hepatic pathologies, particularly intrahepatic cholestatic liver diseases. Central to this composition is an isolated anti-CCL24 (eotaxin 2) antibody, or its antigen-binding fragments, which is characterized as a fully humanized antibody. This antibody includes six complementarity-determining regions (CDRs) as specified by SEQ ID Nos 1-6, along with a heavy chain variable region that exhibits at least 90% sequence homology to SEQ ID NO:7 and a light chain variable region with at least 90% sequence homology to SEQ ID NO:8. The patent emphasizes the application of this composition in treating conditions such as primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), and cholangiocarcinoma resulting from PSC.
Additionally, the claims outline that the pharmaceutical composition may include at least one additional therapeutic agent, enhancing its potential efficacy in treating the specified hepatic diseases. The specificity of the antibody and its humanized nature suggest a targeted approach to therapy, which may improve treatment outcomes for patients suffering from these challenging liver conditions. The patent thus provides a framework for further research and development in the field of hepatic disease treatment, focusing on the role of CCL24 in liver pathology.
To know more about GlobalData’s detailed insights on Chemomab Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
